Keen H L, Sigmund C D
Departments of Internal Medicine and Physiology & Biophysics, University of Iowa College of Medicine, Iowa City, Iowa, USA.
Hypertension. 2001 Feb;37(2 Pt 2):403-7. doi: 10.1161/01.hyp.37.2.403.
We previously reported the generation of transgenic mice containing the entire human renin gene with a 900-bp promoter. To determine whether all the required elements for angiotensin II-mediated suppression of human renin are present in these mice, angiotensin II was chronically infused by means of osmotic minipump at both low and high doses, 200 and 1000 ng/kg per minute, respectively. Blood pressure was measured by tail-cuff, and kidney renin mRNA levels were quantitated using ribonuclease protection assays. Blood pressure was unchanged in mice receiving either vehicle or low-dose angiotensin II infusion but was increased by approximately 40 mm Hg with the higher dose of angiotensin II. Mouse renin mRNA decreased by >60% during both pressor and nonpressor angiotensin II infusion. Human renin mRNA was not suppressed by nonpressor angiotensin II and was paradoxically increased 1.9-fold by pressor angiotensin II. The lack of upregulation during nonpressor angiotensin II suggested that the increase might be pressure-mediated. To test this, the angiotensin II-induced increase in blood pressure was prevented by coadministration of the vasodilator, hydralazine (15 mg/kg per day). Hydralazine alone decreased blood pressure (-27+/-3 mm Hg) and increased mouse renin mRNA 2.4-fold. Human renin mRNA was unresponsive to this vasodilator-induced fall in pressure and despite the normalization of blood pressure by hydralazine, high-dose angiotensin II still caused a 2.1-fold increase in human renin mRNA. Thus, the first 900 bp of the human renin promoter does not contain all the elements required for appropriate angiotensin II-mediated suppression of human renin mRNA.
我们之前报道过生成了含有完整人类肾素基因及900个碱基对启动子的转基因小鼠。为了确定这些小鼠中是否存在血管紧张素II介导的人类肾素抑制所需的所有元件,通过渗透微型泵分别以低剂量和高剂量(每分钟200和1000 ng/kg)长期输注血管紧张素II。通过尾套法测量血压,并使用核糖核酸酶保护试验对肾素mRNA水平进行定量。接受载体或低剂量血管紧张素II输注的小鼠血压未发生变化,但高剂量血管紧张素II使血压升高约40 mmHg。在升压和非升压血管紧张素II输注过程中,小鼠肾素mRNA均下降超过60%。非升压血管紧张素II未抑制人类肾素mRNA,而升压血管紧张素II却使其反常地增加了1.9倍。非升压血管紧张素II期间缺乏上调表明这种增加可能是压力介导的。为了验证这一点,通过同时给予血管扩张剂肼屈嗪(每天15 mg/kg)来预防血管紧张素II引起的血压升高。单独使用肼屈嗪可降低血压(-27±3 mmHg)并使小鼠肾素mRNA增加2.4倍。人类肾素mRNA对这种由血管扩张剂引起的血压下降无反应,并且尽管肼屈嗪使血压恢复正常,但高剂量血管紧张素II仍导致人类肾素mRNA增加2.1倍。因此,人类肾素启动子的前900个碱基对并不包含血管紧张素II介导的人类肾素mRNA适当抑制所需的所有元件。